Dominic P. Williams

Dominic P. Williams

Auto-generated profile, based on publicly available information

Dominic P. Williams

University of Liverpool

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
KJKyung-Jin Jang
Kyung-Jin Jang
MOMonicah A. Otieno
Monicah A. Otieno
JRJaney Ronxhi
Janey Ronxhi
HLHeng-Keang Lim
Heng-Keang Lim
LELorna Ewart
Lorna Ewart
GHGeraldine A. Hamilton
Geraldine A. Hamilton
A rat, dog, and human Liver-Chip designed using microengineered Organs-on-Chips technology recapitulates species-specific drug toxicities.

1 April 2011 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
BPB. Kevin Park
B. Kevin Park
ABAlan Boobis
Alan Boobis
SCStephen Clarke
Stephen Clarke
CGChris E. P. Goldring
Chris E. P. Goldring
DJDavid Jones
David Jones
TBThomas A. Baillie
Thomas A. Baillie

22 September 2005 in Annual Review of Pharmacology and Toxicology
Verified
Journal Article
Closed access
BPB. Kevin Park
B. Kevin Park
NKNeil R. Kitteringham
Neil R. Kitteringham
JMJames L. Maggs
James L. Maggs
MPMunir Pirmohamed
Munir Pirmohamed
DWDominic P. Williams
Dominic P. Williams
▪ Abstract The importance of reactive metabolites in the pathogenesis of drug-induced toxicity has been a focus of research interest since pioneering investigations in the 1950s revealed the link between toxic metabolites and chemical carcinogenesis. There is now a great deal of evidence that shows that reactive metabolites are formed from drugs known to cause hepatotoxicity, but how these toxic species initiate and propagate tissue damage is still poorly understood. This review summarizes the evidence for reactive metabolite formation from hepatotoxic drugs, such as acetaminophen, tamoxifen, diclofenac, and troglitazone, and the current hypotheses of how this leads to liver injury. Several hepatic proteins can be modified by reactive metabolites, but this in general equates poorly with the extent of toxicity. Much more important may be the identification of the critical proteins modified by these toxic species and how this alters their function. It is also important to note that the toxicity of reactive metabolites may be mediated by noncovalent binding mechanisms, which may also have profound effects on normal liver physiology. Technological developments in the wake of the genomic revolution now provide unprecedented power to characterize and quantify covalent modification of individual target proteins and their functional consequences; such information should dramatically improve our understanding of drug-induced hepatotoxic reactions.

13 June 2017 in Archives of Toxicology
Verified
Journal Article
Open access
PDF file
WPWilliam R. Proctor
William R. Proctor
AFAlison J. Foster
Alison J. Foster
JVJennifer Vogt
Jennifer Vogt
CSClaire Summers
Claire Summers
BMBrian Middleton
Brian Middleton
DWDominic Williams
Dominic Williams
Drug-induced liver injury (DILI) continues to be a major source of clinical attrition, precautionary warnings, and post-market withdrawal of drugs. Accordingly, there is a need for more predictive tools to assess hepatotoxicity risk in drug discovery. Three-dimensional (3D) spheroid hepatic cultures have emerged as promising tools to assess mechanisms of hepatotoxicity, as they demonstrate enhanced liver phenotype, metabolic activity, and stability in culture not attainable with conventional two-dimensional hepatic models. Increased sensitivity of these models to drug-induced cytotoxicity has been demonstrated with relatively small panels of hepatotoxicants. However, a comprehensive evaluation of these models is lacking. Here, the predictive value of 3D human liver microtissues (hLiMT) to identify known hepatotoxicants using a panel of 110 drugs with and without clinical DILI has been assessed in comparison to plated two-dimensional primary human hepatocytes (PHH). Compounds were treated long-term (14 days) in hLiMT and acutely (2 days) in PHH to assess drug-induced cytotoxicity over an 8-point concentration range to generate IC50 values. Regardless of comparing IC50 values or exposure-corrected margin of safety values, hLiMT demonstrated increased sensitivity in identifying known hepatotoxicants than PHH, while specificity was consistent across both assays. In addition, hLiMT out performed PHH in correctly classifying hepatotoxicants from different pharmacological classes of molecules. The hLiMT demonstrated sufficient capability to warrant exploratory liver injury biomarker investigation (miR-122, HMGB1, α-GST) in the cell-culture media. Taken together, this study represents the most comprehensive evaluation of 3D spheroid hepatic cultures up to now and supports their utility for hepatotoxicity risk assessment in drug discovery.

1 May 2012 in Journal of Hepatology
Verified
Journal Article
Closed access
DADaniel J. Antoine
Daniel J. Antoine
RJRosalind E. Jenkins
Rosalind E. Jenkins
JDJames W. Dear
James W. Dear
DWDominic P. Williams
Dominic P. Williams
Mitchell McGillMitchell McGill
Mitchell McGill
BPB. Kevin Park
B. Kevin Park

20 November 2019 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
RWRichard J. Weaver
Richard J. Weaver
EBEric A. Blomme
Eric A. Blomme
ACAmy Elizabeth Chadwick
Amy Elizabeth Chadwick
ICIan M. Copple
Ian M. Copple
HGHelga H. J. Gerets
Helga H. J. Gerets
BPB. Kevin Park
B. Kevin Park